Physician profile
Charles Howe
NPI 1568493096
$2,476.01
in general payments reported to CMS, 2019-2025
45 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $151 · 2021: $244 · 2022: $327 · 2023: $663 · 2024: $232 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $268.41 | 2021-2025 | Nuplazid |
| Abbvie INC. | $217.15 | 2022-2025 | |
| Amgen INC. | $133.93 | 2019-2024 | Aimovig |
| Emd Serono, INC. | $118.43 | 2019-2025 | |
| Lilly USA, LLC | $109.45 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Medtronic, INC. | $106.93 | 2022-2023 | Intellis Adaptivestim |
| Vanda Pharmaceuticals INC. | $106.73 | 2025 | Ponvory |
| Argenx US, INC. | $95.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $91.24 | 2019-2021 | |
| Abbott Laboratories | $88.77 | 2022-2023 | Proclaim |
| Biogen, INC. | $76.71 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Sumitomo Pharma America, INC. | $62.27 | 2023 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $60.88 | 2023 | Fycompa |
| Pfizer INC. | $58.75 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $56.65 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.